Navigation Links
Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
Date:1/14/2011

SEATTLE, Jan. 14, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the pricing of a public offering of $540 million aggregate principal amount of 2.875% convertible senior notes due January 15, 2016 (the "Notes") in an offering registered under the Securities Act of 1933, as amended (the "Securities Act"), which was upsized from its previously announced $500 million offering.  The Notes will be convertible into cash, shares of Dendreon's common stock (the "Common Stock") or a combination of cash and shares of Common Stock, at Dendreon's election. Dendreon also granted the underwriter of the offering of the Notes an option to purchase up to an additional $80 million aggregate principal amount of Notes solely to cover overallotments.  The Notes will be the unsecured, senior obligations of Dendreon and will bear interest at a rate of 2.875% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2011.  The offering is expected to close on January 20, 2011, subject to customary closing conditions.

The conversion rate will initially equal 19.5160 shares of Common Stock per $1,000 principal amount of Notes, which corresponds to an initial conversion price of approximately $51.24 per share of Common Stock, representing a conversion premium of 40.00% over $36.60, which was the closing price per share of the Common Stock on January 13, 2011.  The conversion rate is subject to adjustment upon the occurrence of certain events.  

Dendreon estimates that its net proceeds from the offering of the Notes will be approximately $529.2 million (or approximately $607.6 million if the underwriter exercises its overallotment option in full) after deducting underwriting fees and without deducting estimated offering expenses that are payable by Dendreon.  Dendreon intends to use the
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... with the use of special anti-vascular endothelial growth factor agents given by injection ... currently does not have a scientific protocol for the many millions diagnosed with ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... their offering. The markets for gene therapy ... approved gene therapy product and it is marketed in ... markets are estimated for the years 2014-2024. The estimates ...
(Date:9/2/2015)... , September 2, 2015 Biovista ... winners of the 2015 BeHEARD science challenge, a global ... rare disease researchers, access to the latest life science ... drug repositioning and pathway analytics capability to support ... Foundation in the study of Niemann-Pick Disease Type A ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... CMS Software, part of the Elekta ... and workflow management solutions, today announced that ... Cancer Institute has purchased Monaco, the next-generation ... planning system.Featuring biological modeling, constrained optimization, sensitivity ...
... BONITA SPRINGS, Fla., March 4 Tigris Pharmaceuticals, ... announced that its Investigational New Drug (IND) application ... accepted by the U.S. Food and Drug Administration. ... Phase I study evaluating the safety of GGTI-2418 ...
... by Amgen and Wyeth Offers a Chance to Win a ... YORK, March 4 Amgen and ... television host and fashion consultant ("Project Runway," "Tim Gunn,s Guide ... campaign designed to help people with plaque psoriasis get more ...
Cached Biology Technology:Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System 2Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System 3FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418 2Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style 2Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style 3Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style 4Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style 5
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... In recent years, the possible applications for double-walled ... those working on developing renewable energy technologies. These ... thin enough to be transparent, yet can still ... advanced solar panels, sensors and a host of ...
... for Glycomics in collaboration with colleagues at the ... to identifying a broad spectrum treatment for the ... These highly-infectious viruses are the leading cause of ... of hospitalisations in the developed world, and hundreds ...
... Dec. 23, 2008 -- The reproductive spores of many ... to new research by mycologists and applied mathematicians at ... this week in the Proceedings of the National ... fungal spores is within one percent of the absolute ...
Cached Biology News:Researchers find chink in the armor of viral 'tummy bug' 2In many fungi, reproductive spores are remarkably aerodynamic 2